• Conference
  • biomodal presenter
  • In partnership with Illumina

EACR Congress 2026

The 2026 Annual Congress of the European Association for Cancer Research (EACR 2026) is dedicated to basic, preclinical and translational cancer research across a wide breadth of topics. It will highlight the latest research and bring together the cancer research community to inspire innovation and build knowledge, connections and collaborations.
8 June 2026
to 11 June 2026
Hungexpo
, Budapest
, Hungary

Visit biomodal at booth 

#53

Presentations

Explore our resources

Request a meeting

About the event

Meet biomodal at the EACR Congress 2026

biomodal is excited to be part of the European Association for Cancer Research (EACR) Congress 2026, a leading international forum bringing together the cancer research community to share cutting‑edge science, emerging technologies, and new translational insights.

Visit biomodal at Booth 53 to learn why genetics alone doesn’t tell the full story. Explore the 6‑base genome, where 5‑methylcytosine (5mC) and 5‑hydroxymethylcytosine (5hmC) reveal a cell’s dynamic state and early signals of change, helping you predict the future.

  • One Solution: How duet multiomics solution evoC delivers 6‑base data with unrivaled sensitivity and specificity in a single workflow
  • Why conventional sequencing methods aren’t enough: What standard approaches overlook in methylation state changes and gene regulation.
  • Early indicators of disease: How 5mC and 5hmC patterns illuminate activation and identity, and why that matters for detection.

Please join our industry lunch session; Get it all in one workflow: Use duet cfDNA solutions to detect cancer earlier, monitor treatment response and understand tumour biology on Tuesday, 9 June 2026, from 13:30–14:15 in Room F6+F7+F8, where we will host two expert speakers presenting cutting‑edge insights in liquid biopsy and ctDNA analysis.

Would you like to meet up in person? Book your onsite meeting with one of our biomodal attendees by filling out the form below. ⬇️

Presenting at the event

Methylation Meets Fragmentomics: ctDNA in Early Prostate Cancer

Ellen Heitzer

Professor

Medical University of Graz

Tuesday 09 June 2026 | 13:30 - 14:15​ | Room F6+F7+F8​

Early detection of prostate cancer is challenged by low circulating tumor DNA (ctDNA) levels, limiting sensitivity. We evaluated whether combining methylation and fragmentomic features from cell-free DNA (cfDNA) improves detection. cfDNA from prostate cancer patients across disease stages and healthy controls was analyzed using a multiomics approach assessing 5mC, 5hmC, and fragmentomic features. Methylation signals reflected tumor biology but were less sensitive in localized disease, whereas fragmentomics provided more consistent discrimination across stages. Overall, fragmentomics offers a robust basis for early detection, and integrating both marker types is expected to further increase sensitivity and improve non-invasive prostate cancer diagnostics.

Get it all in one workflow: Use duet cfDNA solutions to detect cancer earlier, monitor treatment response and understand tumour biology

Tom Charlesworth

Director of Market Strategy & Corporate Development

biomodal

Tuesday 09 June 2026 | 13:30 - 14:15​ | Room F6+F7+F8​

duet cfDNA solutions are complete integrated genetic and epigenetic workflows and software that unlock the broadest spectrum of biomarkers from a single low input cfDNA sample. The workflows have been engineered for cfDNA applications to maximise the recovery of unique cfDNA molecules. Coupled with the full complement of biomarkers on each DNA fragment, duet cfDNA enables ultra-low LoD for the detection of ctDNA.

The solution provides market-leading 6-base genetic and epigenetic accuracy, including the ability to distinguish 5mC from 5hmC, coupled with fragmentomic information. Providing a full complement of biomarkers on each DNA fragment enables ultra-low LoD for the detection of ctDNA.

6-base data has been shown to detect cancer earlier than other methylation sequencing approaches in multiple cohorts. Furthermore, analysis of cfDNA from a combination therapy clinical trial has demonstrated the power of the 6-base genome for better understanding the biological mechanism of prostate cancer treatment response.

In-booth Poster Presentation: Single stranded ligation enhances the performance of the duet evoC 6-base assay, enhancing value in low DNA input applications including liquid biopsy

Robert Blanshard

Product Manager

biomodal

There is increasing evidence that combining genetic and DNA methylation information in cancer research and diagnostics provides significant utility. For example, bi-allelic inactivation of tumour suppressor genes commonly occurs through a combination of somatic mutation at one allele and epigenetic silencing of the second allele and can be a key driver of cancer progression. In addition, gene fusions have an impact on DNA methylation patterns and DNA methylation changes can provide information on gene fusion status, even where the fusion event itself cannot be confidently identified in genetic sequencing data. Furthermore, combined genetic and epigenetic analysis of individual DNA fragments can increase sensitivity of somatic variant detection, which is particularly important in liquid biopsy applications.

Here we analyse cell-free DNA (cfDNA) using 6-base sequencing with duet evoC, which calls genetic mutations and distinguishes between 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) with high accuracy. We leverage duet evoC to confidently identify circulating-tumor DNA (ctDNA) fragments in cfDNA, a method that can be generally applied to increase the sensitivity of MRD detection. We also demonstrate that bi-allelic inactivation of tumor suppressor genes in patient samples can be identified in a single assay. Further, we identify methylation patterns that are indicative of gene fusions or chromosomal rearrangements, opening the possibility of improving the sensitivity of gene fusion detection in clinical samples.

Our results highlight how duet evoC enables integrated genetic and epigenetic profiling in a single assay, revealing clinically relevant alterations that conventional approaches often miss. This integrated view offers a more sensitive and comprehensive framework for cancer detection and monitoring.

Find the venue

One sample. One workflow. One solution.

Here are the relevant biomodal resources for information. Find poster presentation information, case studies, interviews, and more.

Cancer research

Discover how alterations in DNA methylation play a crucial role in cancer research via gene expression changes and mutation occurrence. Learn more.

Discover more

Attending from biomodal

Leonardo Motta

Leonardo Motta

Territory Account Manager – UK, Ireland & Nordics
Robert Blanshard

Robert Blanshard, PhD

Product Manager
Tom Charlesworth

Tom Charlesworth, PhD

Director of Market Strategy and Corporate Development

Register now

Meet our team at the event

EACR 2026 8-11JUN26
392656668864

Stay up to date

Explore recent biomodal news and the events that we’ll be attending in the near future.

News

Events

What are you looking for?